RFP
ACTU

Root Financial Partners’s Actuate Therapeutics ACTU Stock Holding History

Root Financial Partners’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$14 – 3348
2026
Q1 		$14 Buy
+5
New +$21 ﹤0.01% 3449

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Root Financial Partners's ACTU Position: Q2 2026 in Review

Root Financial Partners sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 5 shares — an estimated $14 sold.

Root Financial Partners first reported a position in ACTU in Q1 2026 and held it in 1 quarter. The position peaked at $14 in Q1 2026. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Root Financial Partners reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 5 Actuate Therapeutics shares in Q2 2026, an estimated $14.
  • Root Financial Partners first reported a position in Actuate Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Actuate Therapeutics position peaked at $14 in Q1 2026.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.